Fourth Quarter 2015 Highlights
- Revenue increased 8% in constant currency to $510.1 million from fourth quarter 2014
- Catalent’s proprietary OptiShell™ softgel technology has been selected for use in OPKO Health’s NDA for a new treatment for chronic kidney disease and vitamin D insufficiency, which has been accepted for review by the US FDA
- Expanded its Singapore GMP-approved clinical services facility to provide secondary packaging and labeling capabilities
- Signed an exclusive licensing agreement with Excelimmune to access its antibody combination therapy (ACT) technology platform
- Added Gregory Lucier and J. Martin Carroll to its Board of Directors
Fiscal Year 2015 Highlights
- Revenue increased 7% in constant currency to $1.83 billion from a year ago
- Gross margin expanded 80 basis points to 33.6% from a year ago
- Adjusted EBITDA increased to $443.1 million which represents a 9% increase in constant currency from a year ago
- Adjusted net income increased 43% to $203.5 million from a year ago
- Completed acquisitions of Micron Technologies, Redwood Bioscience, and Pharmapak Technologies
Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics and
consumer health products, today announced financial results for the
fourth quarter and fiscal year 2015, which ended June 30, 2015.
Fourth quarter 2015 revenue of $510.1 million decreased 2% as reported
but increased 8% in constant currency from $519.6 million in the fourth
quarter a year ago. Fiscal year 2015 revenue was $1.83 billion, with no
change as reported and a 7% increase in constant currency. All three of
the Company’s reporting segments posted revenue growth in constant
currency for the fourth quarter and fiscal year.
Fourth quarter 2015 net earnings attributable to Catalent were $153.7
million, or $1.22 per diluted share, compared to $27.2 million, or $0.36
per diluted share, in the fourth quarter a year ago. Fiscal year 2015
net earnings attributable to Catalent were $212.2 million, or $1.75 per
diluted share, compared to $16.2 million, $0.21 per diluted share for
the same period a year ago. The increase in profitability for the
quarter and fiscal year was primarily related to the release of a
valuation allowance on deferred tax assets of $136.7 million which was
recorded as a tax benefit in the fourth quarter along with a reduction
in net interest expense due to the Company’s lower levels of outstanding
debt compared to the same periods a year ago as a result of the fiscal
year 2015 first quarter initial public offering (IPO).
Fourth quarter 2015 EBITDA from continuing operations was $121.8
million, a decrease of 5% from $127.7 million in the fourth quarter a
year ago. Fiscal year 2015 EBITDA from continuing operations was $360.2
million, a decrease of 4% from $374.4 million for the same period a year
ago.
Fourth quarter 2015 Adjusted EBITDA, as referenced in the GAAP to
non-GAAP reconciliation provided later in this release, was $136.3
million, or 26.7% of revenue, compared to $150.7 million, or 29.0% of
revenue, in the fourth quarter a year ago. Fiscal year 2015 Adjusted
EBITDA was $443.1 million, or 24.2% of revenue, compared to $432.3
million, or 23.7% of revenue, for the same period a year ago. This
represents an increase of 9% year-over-year on a constant currency basis.
Fourth quarter 2015 Adjusted Net Income, as referenced in the GAAP to
non-GAAP reconciliation provided later in this release, was $76.6
million, or $0.61 per diluted share, compared to Adjusted Net Income of
$77.0 million, or $1.01 per diluted share, in the fourth quarter a year
ago. Fiscal year 2015 Adjusted Net Income was $203.5 million, or $1.68
per diluted share, compared to Adjusted Net Income of $142.4 million, or
$1.87 per diluted share, for the same period a year ago.
"Fiscal 2015 was a milestone year in Catalent’s history, and we are very
pleased to have achieved constant currency revenue and profitability
growth across all three of our reporting segments,” said John Chiminski,
President and Chief Executive Officer of Catalent, Inc. “During the
year, we successfully completed our initial public offering, closed
three strategic acquisitions, and continued to invest in our innovative
technologies and products. We believe that ongoing market consolidation
and strong demand for fewer, bigger, and better suppliers in our dynamic
industry position us well for organic growth in 2016 and beyond.”
Fourth Quarter 2015 Segment Highlights
Revenue Highlights by Business Segment
Revenue from the Oral Technologies segment was $318.8 million for the
fourth quarter of fiscal 2015, a decrease of 8% as reported, or an
increase of 3% in constant currency, compared to the fourth quarter a
year ago. This growth was attributable to improved performance in the
softgel and modified release offerings, as well as to higher revenue
from product-participation related activities. Additionally, during the
fourth quarter of 2015, the Company recorded a one-time $6 million
customer contract settlement within its Zydis business.
Revenue from the Development and Clinical Services segment was $124.2
million for the fourth quarter of fiscal 2015, an increase of 18% as
reported, or an increase of 22% in constant currency, over the fourth
quarter a year ago. This increase was related to the Micron acquisition,
which occurred in the second quarter of 2015, as well as to growth in
the Company’s clinical services and integrated oral solids development
and manufacturing offerings, partially offset by declines in clinical
trial activity within Europe.
Revenue from the Medication Delivery Solutions segment was $70.1 million
for the fourth quarter of fiscal 2015, an increase of 2% as reported, or
an increase of 12% in constant currency, over the fourth quarter a year
ago. This growth was primarily attributable to increased revenue from
the Company’s blow-fill-seal technology platform and sterile injectables
business.
Segment EBITDA Highlights
Oral Technologies segment EBITDA in the fourth quarter of 2015 was $99.6
million, a decrease of 12% as reported but essentially unchanged in
constant currency versus the fourth quarter a year ago. This in-line
performance was due to a one-time $6 million contractual settlement
within the Company’s Zydis business, which was offset by unfavorable
product mix.
Development and Clinical Services segment EBITDA in the fourth quarter
of 2015 was $26.3 million, with no change as reported, or an increase of
5% in constant currency. This EBITDA improvement was driven by the
Micron acquisition, as well as by the Company’s integrated oral solids
development and manufacturing offerings.
Medication Delivery Solutions segment EBITDA in the fourth quarter of
2015 was $15.0 million, a decrease of 16% as reported, or 7% in constant
currency. This decrease was primarily attributable to unfavorable
product mix and increased costs as a result of the Redwood acquisition.
Additionally, the fourth quarter of fiscal 2014 included the impact of
$4 million cost capitalization related to a facility expansion related
to our animal health capabilities in the Company’s sterile injectables
business.
Fiscal 2015 Segment Highlights
Revenue Highlights by Business Segment
Revenue from the Oral Technologies segment was $1.14 billion for fiscal
year 2015, a decrease of 3% as reported, or an increase of 5% in
constant currency, over the same period a year ago. This growth was
mainly attributable to strong performance within the modified release
technologies business, higher end-market demand for certain customer
products using the Company’s softgel offering, and stronger revenue from
product participation-related activities.
Revenue from the Development and Clinical Services segment was $438.8
million for fiscal year 2015, an increase of 6% as reported, or 8% in
constant currency, over the same period a year ago. This growth was
primarily attributable to the Micron acquisition and the strong
performance in analytical services.
Revenue from the Medication Delivery Solutions segment was $261.9
million for fiscal year 2015, an increase of 6% as reported, or 13% in
constant currency, over the same period a year ago. The strong
performance was attributable to increased demand for products utilizing
the Company’s blow-fill-seal technology platform, biologics offerings,
and sterile injectable products in Europe.
Segment EBITDA Highlights
Oral Technologies segment EBITDA for fiscal year 2015 was $313.7
million, a decrease of 3% as reported, or an increase of 5% in constant
currency. This growth was driven by increased profit from the Company’s
product participation-related activities, as well as higher revenues and
timing of contractual settlements related to its core manufacturing
operations within the modified release technologies platform, partially
offset by unfavorable softgel product mix.
Development and Clinical Services segment EBITDA for fiscal year 2015
was $93.4 million, an increase of 12% as reported, or 14% in constant
currency. This EBITDA improvement was primarily due to profits
contributed by the Micron acquisition, as well as increased demand for
the Company’s integrated oral solids development and manufacturing
capabilities within analytical services.
Medication Delivery Solutions segment EBITDA for fiscal year 2015 was
$53.9 million, an increase of 11% as reported, or 16% in constant
currency. This increase was primarily attributable to favorable product
mix within the Company’s blow-fill-seal technology platform and
increased profit generated from its biologics offerings, partially
offset by unfavorable revenue mix from sterile injectable products in
Europe.
Additional Financial Highlights
Fourth quarter 2015 gross margin of 35.6% declined 100 basis points from
36.6% in the fourth quarter a year ago. For fiscal year 2015, gross
margin was 33.6%, an increase of 80 basis points, compared to 32.8% for
the same period a year ago. The improvement in gross margin for fiscal
year 2015 was primarily due to the strong business performance, as well
as a favorable shift in revenue mix within the Company’s modified
release technologies business and analytical services integrated
operations, partially offset by an unfavorable shift in softgel product
mix.
Fourth quarter 2015 selling, general and administrative expenses were
$86.9 million and represented 17.0% of revenue, compared to $78.6
million, or 15.1% of revenue, in the fourth quarter a year ago. For
fiscal year 2015, selling, general and administrative expenses were
$337.3 million and represented 18.4% of revenue, compared to $334.8
million, or 18.3% of revenue, for the same period a year ago.
Backlog for the Development and Clinical Services segment was $417.7
million as of June 30, 2015, a 5% increase compared to the third quarter
of fiscal year 2015. The segment also recorded net new business wins of
$143.3 million during the fourth quarter, which represented a 31%
increase year over year. The segment’s trailing-twelve-month
book-to-bill ratio was 1.1x.
Balance Sheet and Liquidity
As of June 30, 2015, Catalent had $1.9 billion in debt, compared to $2.7
billion as of June 30, 2014. During fiscal year 2015, the Company raised
over $1 billion in gross proceeds from its IPO and used the net proceeds
to pay down its highest-cost debt. As of June 30, 2015, Catalent’s
leverage ratio was 3.9x, compared to 6.1x as of June 30, 2014.
Fiscal Year 2016 Outlook
For fiscal year 2016, the Company expects revenue in the range of $1.81
billion to $1.90 billion. Catalent expects Adjusted EBITDA in the range
of $434 million to $457 million and Adjusted Net Income in the range of
$203 million to $226 million. These guidance ranges are consistent with
the organic, constant currency long-term CAGR growth expectations of
4-6% for revenue and 6-8% for Adjusted EBITDA. The Company expects
capital expenditures in the range of $125 million to $135 million and
its fully diluted share count on a weighted average basis for the fiscal
year ending June 30, 2016 in the range of 126 million to 128 million
shares.
Earnings Webcast
The Company’s management will host a webcast to discuss the results at
4:30 p.m. ET today. Catalent invites all interested parties to listen to
the webcast, which will be accessible through Catalent’s website at http://investor.catalent.com.
A supplemental slide presentation will also be available in the
“Investors” section of Catalent’s website prior to the start of the
webcast. The webcast replay, along with the supplemental slides, will be
available for 90 days in the “Investors” section at www.catalent.com.
About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT) is the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics and
consumer health products. With over 80 years serving the industry,
Catalent has proven expertise in bringing more customer products to
market faster, enhancing product performance and ensuring reliable
clinical and commercial product supply. Catalent employs approximately
8,700 people, including over 900 scientists, at 31 facilities across 5
continents and in fiscal 2015 generated more than $1.8 billion in annual
revenue. Catalent is headquartered in Somerset, N.J. For more
information, please visit www.catalent.com.
Non-GAAP Financial Measures
Use of EBITDA from continuing operations, Adjusted EBITDA, Adjusted
Net Income and Segment EBITDA
Management measures operating performance based on consolidated earnings
from continuing operations before interest expense, expense/(benefit)
for income taxes, and depreciation and amortization, and it is adjusted
for the income or loss attributable to non-controlling interest (“EBITDA
from continuing operations”). EBITDA from continuing operations is not
defined under U.S. GAAP and is not a measure of operating income,
operating performance or liquidity presented in accordance with U.S.
GAAP and is subject to important limitations.
The Company believes that the presentation of EBITDA from continuing
operations enhances an investor’s understanding of its financial
performance. The Company believes this measure is a useful financial
metric to assess its operating performance from period to period by
excluding certain items that it believes are not representative of its
core business and uses this measure for business planning purposes.
In addition, given the significant investments that Catalent has made in
the past in property, plant and equipment, depreciation and amortization
expenses represent a meaningful portion of its cost structure. The
Company believes that EBITDA from continuing operations will provide
investors with a useful tool for assessing the comparability between
periods of its ability to generate cash from operations sufficient to
pay taxes, to service debt and to undertake capital expenditures because
it eliminates depreciation and amortization expense. The Company
presents EBITDA from continuing operations in order to provide
supplemental information that it considers relevant for the readers of
the Consolidated Financial Statements, and such information is not meant
to replace or supersede U.S. GAAP measures. The Company’s definition of
EBITDA from continuing operations may not be the same as similarly
titled measures used by other companies.
Catalent evaluates the performance of its segments based on segment
earnings before non-controlling interest, other (income)/expense,
impairments, restructuring costs, interest expense, income tax
expense/(benefit), and depreciation and amortization (“segment EBITDA”).
Moreover, under the Company's credit agreement, its ability to engage in
certain activities, such as incurring certain additional indebtedness,
making certain investments and paying certain dividends, is tied to
ratios based on Adjusted EBITDA, which is not defined under U.S. GAAP
and is subject to important limitations. Adjusted EBITDA is the covenant
compliance measure used in the credit agreement governing debt
incurrence and restricted payments. Because not all companies use
identical calculations, the Company’s presentation of Adjusted EBITDA
may not be comparable to other similarly titled measures of other
companies.
Management also measures operating performance based on Adjusted Net
Income/(loss). Adjusted Net Income/(loss) is not defined under U.S. GAAP
and is not a measure of operating income, operating performance or
liquidity presented in accordance with U.S. GAAP and is subject to
important limitations. For example, Adjusted Net Income excludes the
Company’s non-cash tax expense and does not reflect the impact on
earnings resulting from certain other items. The Company believes that
the presentation of Adjusted Net Income/(loss) enhances an investor’s
understanding of its financial performance. The Company believes this
measure is a useful financial metric to assess its operating performance
from period to period by excluding certain items that it believes are
not representative of its core business and the Company uses this
measure for business planning purposes. The Company defines Adjusted Net
Income/(loss) as net earnings/(loss) adjusted for (1) earnings or loss
of discontinued operations, net of tax, (2) tax expense or income which
is not cash, (3) amortization attributable to purchase accounting and
(4) income or loss from non-controlling interest in its majority-owned
operations. The Company also makes adjustments for other cash and
non-cash items included in the table below, partially offset by its
estimate of the cash taxes saved as a result of such cash and non-cash
items. The Company believes that Adjusted Net Income/(loss) will provide
investors with a useful tool for assessing the comparability between
periods of its ability to generate cash from operations available to its
stockholders. The Company’s definition of Adjusted Net Income/(loss) may
not be the same as similarly titled measures used by other companies.
The most directly comparable GAAP measure to EBITDA from continuing
operations and Adjusted EBITDA is earnings/(loss) from continuing
operations. The most directly comparable GAAP measure to Adjusted Net
Income/(loss) is net earnings/(loss). Included in this release is a
reconciliation of earnings/(loss) from continuing operations to EBITDA
from continuing operations and Adjusted EBITDA and reconciliation of net
earnings/(loss) to Adjusted Net Income.
Use of Constant Currency
As changes in exchange rates are an important factor in understanding
period-to-period comparisons, the Company believes the presentation of
results on a constant currency basis in addition to reported results
helps improve investors’ ability to understand its operating results and
evaluate its performance in comparison to prior periods. Constant
currency information compares results between periods as if exchange
rates had remained constant period over period. The Company uses results
on a constant currency basis as one measure to evaluate its performance.
The Company calculates constant currency by calculating current-year
results using prior-year foreign currency exchange rates. The Company
generally refers to such amounts calculated on a constant currency basis
as excluding the impact of foreign exchange or being on a constant
currency basis. These results should be considered in addition to, not
as a substitute for, results reported in accordance with U.S. GAAP.
Results on a constant currency basis, as the Company presents them, may
not be comparable to similarly titled measures used by other companies
and are not measures of performance presented in accordance with U.S.
GAAP.
Forward-Looking Statements
This release contains both historical and forward-looking statements.
All statements other than statements of historical fact are, or may be
deemed to be, forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements generally can be identified by the use of statements that
include phrases such as “believe,” “expect,” “anticipate,” “intend,”
“estimate,” “plan,” “project,” “foresee,” “likely,” “may,” “will,”
“would” or other words or phrases with similar meanings. Similarly,
statements that describe the Company’s objectives, plans or goals are,
or may be, forward-looking statements. These statements are based on
current expectations of future events. If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual results
could vary materially from Catalent, Inc.’s expectations and
projections. Some of the factors that could cause actual results to
differ include, but are not limited to, the following: participation in
a highly competitive market and increased competition may adversely
affect the business of the Company; demand for the Company’s offerings
which depends in part on the Company’s customers’ research and
development and the clinical and market success of their products;
product and other liability risks that could adversely affect the
Company’s results of operations, financial condition, liquidity and cash
flows; failure to comply with existing and future regulatory
requirements; failure to provide quality offerings to customers could
have an adverse effect on the Company’s business and subject it to
regulatory actions and costly litigation; problems providing the highly
exacting and complex services or support required; global economic,
political and regulatory risks to the operations of the Company;
inability to enhance existing or introduce new technology or service
offerings in a timely manner; inadequate patents, copyrights, trademarks
and other forms of intellectual property protections; fluctuations in
the costs, availability, and suitability of the components of the
products the Company manufactures, including active pharmaceutical
ingredients, excipients, purchased components and raw materials; changes
in market access or healthcare reimbursement in the United States or
internationally; fluctuations in the exchange rate of the U.S. dollar
and other foreign currencies; adverse tax legislation initiatives or
challenges to the Company’s tax positions; loss of key personnel; risks
generally associated with information systems; inability to complete any
future acquisitions and other transactions that may complement or expand
the business of the Company or divest of non-strategic businesses or
assets and the Company’s ability to successfully integrate acquired
business and realize anticipated benefits of such acquisitions;
offerings and customers’ products that may infringe on the intellectual
property rights of third parties; environmental, health and safety laws
and regulations, which could increase costs and restrict operations;
labor and employment laws and regulations; additional cash contributions
required to fund the Company’s existing pension plans; substantial
leverage resulting in the limited ability of the Company to raise
additional capital to fund operations and react to changes in the
economy or in the industry, exposure to interest rate risk to the extent
of the Company’s variable rate debt and preventing the Company from
meeting its obligations under its indebtedness. For a more detailed
discussion of these and other factors, see the information under the
caption “Risk Factors” in the Company’s Annual Report on Form 10-K for
the fiscal year ended June 30, 2015, filed with the Securities and
Exchange Commission. All forward-looking statements speak only as of the
date of this release or as of the date they are made, and Catalent, Inc.
does not undertake to update any forward-looking statement as a result
of new information or future events or developments except to the extent
required by law.
More products. Better treatments. Reliably supplied.™
|
|
|
Catalent, Inc. and Subsidiaries
|
|
|
Consolidated Statements of Operations
|
|
|
(Unaudited; Dollars in millions, except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30,
|
|
|
|
FX impact (unfavorable) /favorable
|
|
|
|
Constant Currency Increase/(Decrease)
|
|
|
|
|
|
|
|
2015
|
|
|
|
2014
|
|
|
|
|
|
|
|
Change $
|
|
|
|
Change %
|
|
|
Net revenue
|
|
|
|
|
$
|
|
|
510.1
|
|
|
|
|
$
|
|
|
519.6
|
|
|
|
|
$
|
(51.9
|
)
|
|
|
|
$
|
|
|
42.4
|
|
|
|
|
8
|
%
|
|
|
|
Cost of sales
|
|
|
|
|
328.4
|
|
|
|
|
329.3
|
|
|
|
|
(36.3
|
)
|
|
|
|
35.4
|
|
|
|
|
11
|
%
|
|
|
|
Gross margin
|
|
|
|
|
181.7
|
|
|
|
|
190.3
|
|
|
|
|
(15.6
|
)
|
|
|
|
7.0
|
|
|
|
|
4
|
%
|
|
|
|
Selling, general and administrative expenses
|
|
|
|
|
86.9
|
|
|
|
|
78.6
|
|
|
|
|
(5.0
|
)
|
|
|
|
13.3
|
|
|
|
|
17
|
%
|
|
|
|
Impairment charges and (gain)/loss on sale of assets
|
|
|
|
|
0.9
|
|
|
|
|
2.8
|
|
|
|
|
(0.1
|
)
|
|
|
|
(1.8
|
)
|
|
|
|
(64
|
)%
|
|
|
|
Restructuring and other
|
|
|
|
|
4.7
|
|
|
|
|
7.8
|
|
|
|
|
(0.7
|
)
|
|
|
|
(2.4
|
)
|
|
|
|
(31
|
)%
|
|
|
|
Operating earnings/(loss)
|
|
|
|
|
89.2
|
|
|
|
|
101.1
|
|
|
|
|
(9.8
|
)
|
|
|
|
(2.1
|
)
|
|
|
|
(2
|
)%
|
|
|
|
Interest expense, net
|
|
|
|
|
22.6
|
|
|
|
|
40.3
|
|
|
|
|
—
|
|
|
|
|
(17.7
|
)
|
|
|
|
(44
|
)%
|
|
|
|
Other (income)/expense, net
|
|
|
|
|
3.9
|
|
|
|
|
7.6
|
|
|
|
|
1.3
|
|
|
|
|
(5.0
|
)
|
|
|
|
(66
|
)%
|
|
|
|
Earnings/(loss) from continuing operations, before income taxes
|
|
|
|
|
62.7
|
|
|
|
|
53.2
|
|
|
|
|
(11.1
|
)
|
|
|
|
20.6
|
|
|
|
|
39
|
%
|
|
|
|
Income tax expense/(benefit)
|
|
|
|
|
(90.8
|
)
|
|
|
|
26.2
|
|
|
|
|
(2.5
|
)
|
|
|
|
(114.5
|
)
|
|
|
|
*
|
|
|
Earnings/(loss) from continuing operations
|
|
|
|
|
153.5
|
|
|
|
|
27.0
|
|
|
|
|
(8.6
|
)
|
|
|
|
135.1
|
|
|
|
|
*
|
|
|
Net earnings/(loss) from discontinued operations, net of tax
|
|
|
|
|
(0.1
|
)
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
(0.1
|
)
|
|
|
|
*
|
|
|
Net earnings/(loss)
|
|
|
|
|
153.4
|
|
|
|
|
27.0
|
|
|
|
|
(8.6
|
)
|
|
|
|
135.0
|
|
|
|
|
*
|
|
|
Less: Net earnings/(loss) attributable to noncontrolling interest,
net of tax
|
|
|
|
|
(0.3
|
)
|
|
|
|
(0.2
|
)
|
|
|
|
0.1
|
|
|
|
|
(0.2
|
)
|
|
|
|
*
|
|
|
Net earnings/(loss) attributable to Catalent
|
|
|
|
|
$
|
|
|
153.7
|
|
|
|
|
$
|
|
|
27.2
|
|
|
|
|
$
|
(8.7
|
)
|
|
|
|
$
|
|
|
135.2
|
|
|
|
|
*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amounts attributable to Catalent:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings/(loss) from continuing operations less net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
income (loss) attributable to noncontrolling interest
|
|
|
|
|
153.8
|
|
|
|
|
27.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings/(loss) attributable to Catalent
|
|
|
|
|
153.7
|
|
|
|
|
27.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average diluted shares outstanding
|
|
|
|
|
126.2
|
|
|
|
|
76.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share attributable to Catalent:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings/(loss) from continuing operations
|
|
|
|
|
1.23
|
|
|
|
|
0.36
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings/(loss)
|
|
|
|
|
1.23
|
|
|
|
|
0.36
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings/(loss) from continuing operations
|
|
|
|
|
1.22
|
|
|
|
|
0.36
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings/(loss)
|
|
|
|
|
1.22
|
|
|
|
|
0.36
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* - percentage not meaningful
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Catalent, Inc. and Subsidiaries
|
|
|
Selected Segment Financial Data
|
|
|
(Unaudited; Dollars in millions)
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30,
|
|
|
|
FX impact (unfavorable) / favorable
|
|
|
|
Constant Currency Increase/(Decrease)
|
|
|
|
|
|
|
|
2015
|
|
|
|
2014
|
|
|
|
|
|
|
|
Change $
|
|
|
|
Change %
|
|
|
Oral Technologies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue
|
|
|
|
|
$
|
|
|
|
318.8
|
|
|
|
|
$
|
|
|
|
348.1
|
|
|
|
|
$
|
(40.7
|
)
|
|
|
|
$
|
|
|
|
11.4
|
|
|
|
|
3
|
%
|
|
|
Segment EBITDA
|
|
|
|
|
99.6
|
|
|
|
|
113.1
|
|
|
|
|
(11.5
|
)
|
|
|
|
(2.0
|
)
|
|
|
|
(2
|
)%
|
|
|
Medication Delivery Solutions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue
|
|
|
|
|
70.1
|
|
|
|
|
68.9
|
|
|
|
|
(7.1
|
)
|
|
|
|
8.3
|
|
|
|
|
12
|
%
|
|
|
Segment EBITDA
|
|
|
|
|
15.0
|
|
|
|
|
17.8
|
|
|
|
|
(1.6
|
)
|
|
|
|
(1.2
|
)
|
|
|
|
(7
|
)%
|
|
|
Development and Clinical Services
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue
|
|
|
|
|
124.2
|
|
|
|
|
105.4
|
|
|
|
|
(4.1
|
)
|
|
|
|
22.9
|
|
|
|
|
22
|
%
|
|
|
Segment EBITDA
|
|
|
|
|
26.3
|
|
|
|
|
26.3
|
|
|
|
|
(1.4
|
)
|
|
|
|
1.4
|
|
|
|
|
5
|
%
|
|
|
Inter-segment revenue elimination
|
|
|
|
|
(3.0
|
)
|
|
|
|
(2.8
|
)
|
|
|
|
—
|
|
|
|
|
(0.2
|
)
|
|
|
|
7
|
%
|
|
|
Unallocated Costs
|
|
|
|
|
(19.1
|
)
|
|
|
|
(29.5
|
)
|
|
|
|
(0.1
|
)
|
|
|
|
10.5
|
|
|
|
|
(36
|
)%
|
|
|
Combined Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue
|
|
|
|
|
$
|
|
|
|
510.1
|
|
|
|
|
$
|
|
|
|
519.6
|
|
|
|
|
$
|
(51.9
|
)
|
|
|
|
$
|
|
|
|
42.4
|
|
|
|
|
8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA from continuing operations
|
|
|
|
|
$
|
|
|
|
121.8
|
|
|
|
|
$
|
|
|
|
127.7
|
|
|
|
|
$
|
(14.6
|
)
|
|
|
|
$
|
|
|
|
8.7
|
|
|
|
|
7
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Catalent, Inc. and Subsidiaries
|
|
|
Consolidated Statements of Operations
|
|
|
(Unaudited; Dollars in millions, except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
Twelve Months Ended June 30,
|
|
|
|
FX impact (unfavorable)/ favorable
|
|
|
|
Constant Currency Increase/(Decrease)
|
|
|
|
|
|
|
|
2015
|
|
|
|
2014
|
|
|
|
|
|
|
|
Change $
|
|
|
|
Change %
|
|
|
Net revenue
|
|
|
|
|
$
|
|
|
|
1,830.8
|
|
|
|
|
$
|
|
|
|
1,827.7
|
|
|
|
|
$
|
(117.9
|
)
|
|
|
|
$
|
|
|
|
121.0
|
|
|
|
|
7
|
%
|
|
|
Cost of sales
|
|
|
|
|
1,215.5
|
|
|
|
|
1,229.1
|
|
|
|
|
(82.2
|
)
|
|
|
|
68.6
|
|
|
|
|
6
|
%
|
|
|
Gross margin
|
|
|
|
|
615.3
|
|
|
|
|
598.6
|
|
|
|
|
(35.7
|
)
|
|
|
|
52.4
|
|
|
|
|
9
|
%
|
|
|
Selling, general and administrative expenses
|
|
|
|
|
337.3
|
|
|
|
|
334.8
|
|
|
|
|
(11.0
|
)
|
|
|
|
13.5
|
|
|
|
|
4
|
%
|
|
|
Impairment charges and (gain)/loss on sale of assets
|
|
|
|
|
4.7
|
|
|
|
|
3.2
|
|
|
|
|
(0.1
|
)
|
|
|
|
1.6
|
|
|
|
|
50
|
%
|
|
|
Restructuring and other
|
|
|
|
|
13.4
|
|
|
|
|
19.7
|
|
|
|
|
(2.0
|
)
|
|
|
|
(4.3
|
)
|
|
|
|
(22
|
)%
|
|
|
Operating earnings/(loss)
|
|
|
|
|
259.9
|
|
|
|
|
240.9
|
|
|
|
|
(22.6
|
)
|
|
|
|
41.6
|
|
|
|
|
17
|
%
|
|
|
Interest expense, net
|
|
|
|
|
105.0
|
|
|
|
|
163.1
|
|
|
|
|
(1.2
|
)
|
|
|
|
(56.9
|
)
|
|
|
|
(35
|
)%
|
|
|
Other (income)/expense, net
|
|
|
|
|
42.4
|
|
|
|
|
10.4
|
|
|
|
|
(5.2
|
)
|
|
|
|
37.2
|
|
|
|
|
*
|
|
|
Earnings/(loss) from continuing operations before income taxes
|
|
|
|
|
112.5
|
|
|
|
|
67.4
|
|
|
|
|
(16.2
|
)
|
|
|
|
61.3
|
|
|
|
|
91
|
%
|
|
|
Income tax expense/(benefit)
|
|
|
|
|
(97.7
|
)
|
|
|
|
49.5
|
|
|
|
|
(4.3
|
)
|
|
|
|
(142.9
|
)
|
|
|
|
*
|
|
|
Earnings/(loss) from continuing operations
|
|
|
|
|
210.2
|
|
|
|
|
17.9
|
|
|
|
|
(11.9
|
)
|
|
|
|
204.2
|
|
|
|
|
*
|
|
|
Net earnings/(loss) from discontinued operations, net of tax
|
|
|
|
|
0.1
|
|
|
|
|
(2.7
|
)
|
|
|
|
—
|
|
|
|
|
2.8
|
|
|
|
|
*
|
|
|
Net earnings/(loss)
|
|
|
|
|
210.3
|
|
|
|
|
15.2
|
|
|
|
|
(11.9
|
)
|
|
|
|
207.0
|
|
|
|
|
*
|
|
|
Less: Net earnings/(loss) attributable to noncontrolling interest,
net of tax
|
|
|
|
|
(1.9
|
)
|
|
|
|
(1.0
|
)
|
|
|
|
0.1
|
|
|
|
|
(1.0
|
)
|
|
|
|
*
|
|
|
Net earnings/(loss) attributable to Catalent
|
|
|
|
|
$
|
|
|
|
212.2
|
|
|
|
|
$
|
|
|
|
16.2
|
|
|
|
|
$
|
(12.0
|
)
|
|
|
|
$
|
|
|
|
208.0
|
|
|
|
|
*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amounts attributable to Catalent:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings/(loss) from continuing operations less net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
income (loss) attributable to noncontrolling interest
|
|
|
|
|
212.1
|
|
|
|
|
18.9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings/(loss) attributable to Catalent
|
|
|
|
|
212.2
|
|
|
|
|
16.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average diluted shares outstanding
|
|
|
|
|
121.3
|
|
|
|
|
76.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share attributable to Catalent:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings/(loss) from continuing operations
|
|
|
|
|
1.77
|
|
|
|
|
0.25
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings/(loss)
|
|
|
|
|
1.77
|
|
|
|
|
0.22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings/(loss) from continuing operations
|
|
|
|
|
1.75
|
|
|
|
|
0.25
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings/(loss)
|
|
|
|
|
1.75
|
|
|
|
|
0.21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* - percentage not meaningful
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Catalent, Inc. and Subsidiaries
|
|
|
Selected Segment Financial Data
|
|
|
(Unaudited; Dollars in millions)
|
|
|
|
|
|
|
|
|
|
|
Twelve Months Ended June 30,
|
|
|
|
FX impact (unfavorable) / favorable
|
|
|
|
Constant Currency Increase/(Decrease)
|
|
|
|
|
|
|
|
2015
|
|
|
|
2014
|
|
|
|
|
|
|
|
Change $
|
|
|
|
Change %
|
|
|
Oral Technologies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue
|
|
|
|
|
$
|
|
|
|
1,141.1
|
|
|
|
|
$
|
|
|
|
1,180.1
|
|
|
|
|
$
|
(95.7
|
)
|
|
|
|
$
|
|
|
|
56.7
|
|
|
|
|
5
|
%
|
|
|
Segment EBITDA
|
|
|
|
|
313.7
|
|
|
|
|
324.3
|
|
|
|
|
(27.7
|
)
|
|
|
|
17.1
|
|
|
|
|
5
|
%
|
|
|
Medication Delivery Solutions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue
|
|
|
|
|
261.9
|
|
|
|
|
246.1
|
|
|
|
|
(15.3
|
)
|
|
|
|
31.1
|
|
|
|
|
13
|
%
|
|
|
Segment EBITDA
|
|
|
|
|
53.9
|
|
|
|
|
48.7
|
|
|
|
|
(2.5
|
)
|
|
|
|
7.7
|
|
|
|
|
16
|
%
|
|
|
Development and Clinical Services
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue
|
|
|
|
|
438.8
|
|
|
|
|
412.2
|
|
|
|
|
(7.0
|
)
|
|
|
|
33.6
|
|
|
|
|
8
|
%
|
|
|
Segment EBITDA
|
|
|
|
|
93.4
|
|
|
|
|
83.5
|
|
|
|
|
(2.2
|
)
|
|
|
|
12.1
|
|
|
|
|
14
|
%
|
|
|
Inter-segment revenue elimination
|
|
|
|
|
(11.0
|
)
|
|
|
|
(10.7
|
)
|
|
|
|
0.1
|
|
|
|
|
(0.4
|
)
|
|
|
|
4
|
%
|
|
|
Unallocated Costs
|
|
|
|
|
(100.8
|
)
|
|
|
|
(82.1
|
)
|
|
|
|
7.5
|
|
|
|
|
(26.2
|
)
|
|
|
|
32
|
%
|
|
|
Combined Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue
|
|
|
|
|
$
|
|
|
|
1,830.8
|
|
|
|
|
$
|
|
|
|
1,827.7
|
|
|
|
|
$
|
(117.9
|
)
|
|
|
|
$
|
|
|
|
121.0
|
|
|
|
|
7
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA from continuing operations
|
|
|
|
|
$
|
|
|
|
360.2
|
|
|
|
|
$
|
|
|
|
374.4
|
|
|
|
|
$
|
(24.9
|
)
|
|
|
|
$
|
|
|
|
10.7
|
|
|
|
|
3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Catalent, Inc. and Subsidiaries
|
|
|
Reconciliation of Earnings/(Loss) from Continuing Operations to
EBITDA from Continuing Operations and
|
|
|
Adjusted EBITDA
|
|
|
(Unaudited; Dollars in millions)
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended
|
|
|
|
Twelve Months Ended
|
|
|
|
Quarter Ended
|
|
|
|
Twelve Months Ended
|
|
|
|
|
|
|
|
June 30 2014
|
|
|
|
June 30 2014
|
|
|
|
September 30 2014
|
|
|
|
December 31 2014
|
|
|
|
March 31 2015
|
|
|
|
June 30 2015
|
|
|
|
June 30 2015
|
|
|
Earnings/(loss) from continuing operations
|
|
|
|
|
$
|
|
|
|
27.0
|
|
|
|
|
17.9
|
|
|
|
|
$
|
(20.3
|
)
|
|
|
|
$
|
|
|
|
46.2
|
|
|
|
|
$
|
|
|
|
30.8
|
|
|
|
|
$
|
|
|
|
153.5
|
|
|
|
|
$
|
|
|
|
210.2
|
|
|
|
Interest expense, net
|
|
|
|
|
40.3
|
|
|
|
|
163.1
|
|
|
|
|
35.5
|
|
|
|
|
23.9
|
|
|
|
|
23.0
|
|
|
|
|
22.6
|
|
|
|
|
105.0
|
|
|
|
Income tax expense/(benefit) (1)
|
|
|
|
|
26.2
|
|
|
|
|
49.5
|
|
|
|
|
(14.0
|
)
|
|
|
|
(4.1
|
)
|
|
|
|
11.2
|
|
|
|
|
(90.8
|
)
|
|
|
|
(97.7
|
)
|
|
|
Depreciation and amortization
|
|
|
|
|
34.0
|
|
|
|
|
142.9
|
|
|
|
|
35.0
|
|
|
|
|
35.2
|
|
|
|
|
34.4
|
|
|
|
|
36.2
|
|
|
|
|
140.8
|
|
|
|
Noncontrolling interest
|
|
|
|
|
0.2
|
|
|
|
|
1.0
|
|
|
|
|
0.4
|
|
|
|
|
0.5
|
|
|
|
|
0.7
|
|
|
|
|
0.3
|
|
|
|
|
1.9
|
|
|
|
EBITDA from continuing operations
|
|
|
|
|
127.7
|
|
|
|
|
374.4
|
|
|
|
|
36.6
|
|
|
|
|
101.7
|
|
|
|
|
100.1
|
|
|
|
|
121.8
|
|
|
|
|
360.2
|
|
|
|
Equity compensation
|
|
|
|
|
1.1
|
|
|
|
|
4.5
|
|
|
|
|
1.5
|
|
|
|
|
2.7
|
|
|
|
|
2.2
|
|
|
|
|
2.6
|
|
|
|
|
9.0
|
|
|
|
Impairment charges and (gain)/loss on sale of assets
|
|
|
|
|
2.8
|
|
|
|
|
3.2
|
|
|
|
|
—
|
|
|
|
|
3.5
|
|
|
|
|
0.3
|
|
|
|
|
0.9
|
|
|
|
|
4.7
|
|
|
|
Financing related expenses
and other (2)
|
|
|
|
|
10.9
|
|
|
|
|
11.0
|
|
|
|
|
20.6
|
|
|
|
|
1.2
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
21.8
|
|
|
|
US GAAP Restructuring
|
|
|
|
|
7.8
|
|
|
|
|
19.7
|
|
|
|
|
1.4
|
|
|
|
|
2.1
|
|
|
|
|
5.2
|
|
|
|
|
4.7
|
|
|
|
|
13.4
|
|
|
|
Acquisition, integration and other special items
|
|
|
|
|
0.6
|
|
|
|
|
9.8
|
|
|
|
|
3.2
|
|
|
|
|
4.4
|
|
|
|
|
2.5
|
|
|
|
|
3.7
|
|
|
|
|
13.8
|
|
|
|
Foreign Exchange loss/(gain) (included in other, net) (3)
|
|
|
|
|
(3.8
|
)
|
|
|
|
(3.5
|
)
|
|
|
|
(3.7
|
)
|
|
|
|
0.5
|
|
|
|
|
(1.0
|
)
|
|
|
|
1.5
|
|
|
|
|
(2.7
|
)
|
|
|
Other adjustments (4)
|
|
|
|
|
0.4
|
|
|
|
|
0.3
|
|
|
|
|
23.8
|
|
|
|
|
(3.2
|
)
|
|
|
|
1.2
|
|
|
|
|
1.1
|
|
|
|
|
22.9
|
|
|
|
Sponsor monitoring fee (5)
|
|
|
|
|
3.2
|
|
|
|
|
12.9
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
Subtotal
|
|
|
|
|
150.7
|
|
|
|
|
432.3
|
|
|
|
|
83.4
|
|
|
|
|
112.9
|
|
|
|
|
110.5
|
|
|
|
|
136.3
|
|
|
|
|
443.1
|
|
|
|
Estimated cost savings
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
Adjusted EBITDA
|
|
|
|
|
$
|
|
|
|
150.7
|
|
|
|
|
$
|
|
|
|
432.3
|
|
|
|
|
$
|
83.4
|
|
|
|
|
$
|
|
|
|
112.9
|
|
|
|
|
$
|
|
|
|
110.5
|
|
|
|
|
$
|
|
|
|
136.3
|
|
|
|
|
$
|
|
|
|
443.1
|
|
|
|
FX impact (unfavorable)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(27.5
|
)
|
|
|
Adjusted EBITDA - Constant Currency
|
|
|
|
|
|
|
|
|
432.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
470.6
|
|
|
|
(1)
|
|
Represents the amount of income tax-related expense/(benefit)
recorded within our net earnings/(loss) that may not result in cash
payment or receipt.
|
|
|
|
(2)
|
|
Financing related expenses for the three months ended September 30,
2014 include $20.6 million of early debt termination expenses
incurred in connection with the repayment of debt with the net
proceeds of the IPO. See footnote 4 for an additional $29.8 million
of IPO-related costs; totaling $50.4 million.
|
|
|
|
(3)
|
|
Foreign exchange gain of $2.7 million for the twelve months ended
June 30, 2015 included $16.4 million of unrealized foreign currency
exchange rate gains primarily driven by losses of $31.4 million
related to inter-company loans denominated in a currency different
from the functional currency of either the borrower or the lender,
partially offset by foreign currency exchange gains of $47.8 million
driven by the ineffective portion of the net investment hedge
related to the Euro denominated debt. The foreign exchange
adjustment was also affected by the exclusion of realized foreign
currency exchange rate losses from the non-cash and cash settlement
of inter-company loans of $13.7 million. Inter-company loans are
between Catalent entities and do not reflect the ongoing results of
the company's trade operations.
|
|
|
|
(4)
|
|
Other Adjustments for the three months ended September 30, 2014
includes $29.8 million for a sponsor advisory agreement termination
fee paid in connection with the IPO. See footnote 2 for an
additional $20.6 million of IPO-related costs; totaling $50.4
million.
|
|
|
|
(5)
|
|
Represents the amount of sponsor advisory fee for each respective
period. The sponsor advisory fee agreement was terminated in
connection with the completion of our IPO.
|
|
|
|
|
|
|
Catalent, Inc. and Subsidiaries
|
|
|
Reconciliation of Net Earnings/(Loss) to Adjusted Net
Income/(Loss)
|
|
|
(Unaudited; Dollars in millions)
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended
|
|
|
|
|
Twelve Months Ended
|
|
|
|
Quarter Ended
|
|
|
|
Twelve Months Ended
|
|
|
|
|
|
|
|
June 30 2014
|
|
|
|
|
June 30 2014
|
|
|
|
September 30 2014
|
|
|
|
December 31 2014
|
|
|
|
March 31 2015
|
|
|
|
June 30 2015
|
|
|
|
June 30 2015
|
|
|
Net earnings/(loss)
|
|
|
|
|
$
|
|
|
|
27.0
|
|
|
|
|
|
$
|
|
|
|
15.2
|
|
|
|
|
$
|
(19.9
|
)
|
|
|
|
$
|
46.0
|
|
|
|
|
$
|
|
|
|
30.8
|
|
|
|
|
$
|
|
|
|
153.4
|
|
|
|
|
$
|
|
|
|
210.3
|
|
|
|
Net earnings/(loss) from discontinued operations, net of tax
|
|
|
|
|
—
|
|
|
|
|
|
(2.7
|
)
|
|
|
|
0.4
|
|
|
|
|
(0.2
|
)
|
|
|
|
—
|
|
|
|
|
(0.1
|
)
|
|
|
|
0.1
|
|
|
|
Earnings/(loss) from continuing operations, net of tax
|
|
|
|
|
27.0
|
|
|
|
|
|
17.9
|
|
|
|
|
(20.3
|
)
|
|
|
|
46.2
|
|
|
|
|
30.8
|
|
|
|
|
153.5
|
|
|
|
|
210.2
|
|
|
|
Amortization (1)
|
|
|
|
|
10.8
|
|
|
|
|
|
42.5
|
|
|
|
|
11.3
|
|
|
|
|
11.6
|
|
|
|
|
11.8
|
|
|
|
|
11.8
|
|
|
|
|
46.5
|
|
|
|
Income tax expense/(benefit) (2)
|
|
|
|
|
26.2
|
|
|
|
|
|
49.5
|
|
|
|
|
(14.0
|
)
|
|
|
|
(4.1
|
)
|
|
|
|
11.2
|
|
|
|
|
(90.8
|
)
|
|
|
|
(97.7
|
)
|
|
|
Cash taxes (paid)/refunded
|
|
|
|
|
(7.6
|
)
|
|
|
|
|
(21.1
|
)
|
|
|
|
(9.9
|
)
|
|
|
|
(8.2
|
)
|
|
|
|
(5.6
|
)
|
|
|
|
(10.8
|
)
|
|
|
|
(34.5
|
)
|
|
|
Net (earnings)/loss attributable to noncontrolling interest,
net of tax
|
|
|
|
|
0.2
|
|
|
|
|
|
1.0
|
|
|
|
|
0.4
|
|
|
|
|
0.5
|
|
|
|
|
0.7
|
|
|
|
|
0.3
|
|
|
|
|
1.9
|
|
|
|
Equity compensation
|
|
|
|
|
1.1
|
|
|
|
|
|
4.5
|
|
|
|
|
1.5
|
|
|
|
|
2.7
|
|
|
|
|
2.2
|
|
|
|
|
2.6
|
|
|
|
|
9.0
|
|
|
|
Impairment charges and loss on sale of assets
|
|
|
|
|
2.8
|
|
|
|
|
|
3.2
|
|
|
|
|
—
|
|
|
|
|
3.5
|
|
|
|
|
0.3
|
|
|
|
|
0.9
|
|
|
|
|
4.7
|
|
|
|
Financing related expenses (3)
|
|
|
|
|
10.9
|
|
|
|
|
|
11.0
|
|
|
|
|
20.6
|
|
|
|
|
1.2
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
21.8
|
|
|
|
U.S. GAAP restructuring
|
|
|
|
|
7.8
|
|
|
|
|
|
19.7
|
|
|
|
|
1.4
|
|
|
|
|
2.1
|
|
|
|
|
5.2
|
|
|
|
|
4.7
|
|
|
|
|
13.4
|
|
|
|
Acquisition, integration and other special items
|
|
|
|
|
0.6
|
|
|
|
|
|
9.8
|
|
|
|
|
3.2
|
|
|
|
|
4.4
|
|
|
|
|
2.5
|
|
|
|
|
3.7
|
|
|
|
|
13.8
|
|
|
|
Foreign exchange loss/(gain) (included in other
(income)/expense, net) (4)
|
|
|
|
|
(3.8
|
)
|
|
|
|
|
(3.5
|
)
|
|
|
|
(3.7
|
)
|
|
|
|
0.5
|
|
|
|
|
(1.0
|
)
|
|
|
|
1.5
|
|
|
|
|
(2.7
|
)
|
|
|
Other adjustments (5)
|
|
|
|
|
0.4
|
|
|
|
|
|
0.3
|
|
|
|
|
23.8
|
|
|
|
|
(3.2
|
)
|
|
|
|
1.2
|
|
|
|
|
1.1
|
|
|
|
|
22.9
|
|
|
|
Sponsor advisory fee (6)
|
|
|
|
|
3.2
|
|
|
|
|
|
12.9
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
Estimated cash tax (savings)/expense attributable to
reconciling items (7)
|
|
|
|
|
(2.6
|
)
|
|
|
|
|
(5.3
|
)
|
|
|
|
(0.9
|
)
|
|
|
|
(1.3
|
)
|
|
|
|
(1.7
|
)
|
|
|
|
(1.9
|
)
|
|
|
|
(5.8
|
)
|
|
|
Adjusted net income/(loss)
|
|
|
|
|
$
|
|
|
|
77.0
|
|
|
|
|
|
$
|
|
|
|
142.4
|
|
|
|
|
$
|
13.4
|
|
|
|
|
$
|
55.9
|
|
|
|
|
$
|
|
|
|
57.6
|
|
|
|
|
$
|
|
|
|
76.6
|
|
|
|
|
$
|
|
|
|
203.5
|
|
|
|
(1)
|
|
Represents the amortization attributable to purchase accounting for
previously completed business combinations.
|
|
|
|
(2)
|
|
Represents the amount of income tax-related expense/(benefit)
recorded within our net earnings/(loss) that may not result in cash
payment or receipt.
|
|
|
|
(3)
|
|
Financing related expenses for the three months ended September 30,
2014 include $20.6 million of early debt termination expenses
incurred in connection with the repayment of debt with the net
proceeds of the IPO. See footnote 5 for an additional $29.8 million
of IPO-related costs; totaling $50.4 million.
|
|
|
|
(4)
|
|
Foreign exchange gain of $2.7 million for the twelve months ended
June 30, 2015 included $16.4 million of unrealized foreign currency
exchange rate gains primarily driven by losses of $31.4 million
related to inter-company loans denominated in a currency different
from the functional currency of either the borrower or the lender,
partially offset by foreign currency exchange gains of $47.8 million
driven by the ineffective portion of the net investment hedge
related to the Euro denominated debt. The foreign exchange
adjustment was also affected by the exclusion of realized foreign
currency exchange rate losses from the non-cash and cash settlement
of inter-company loans of $13.7 million. Inter-company loans are
between Catalent entities and do not reflect the ongoing results of
the company's trade operations.
|
|
|
|
(5)
|
|
Other Adjustments for the three months ended September 30, 2014
includes $29.8 million for a sponsor advisory agreement termination
fee paid in connection with the IPO. See footnote 3 for an
additional $20.6 million of IPO-related costs; totaling $50.4
million.
|
|
|
|
(6)
|
|
Represents the amount of sponsor advisory fee for each respective
period. The sponsor advisory fee agreement was terminated in
connection with the completion of our IPO.
|
|
|
|
(7)
|
|
Represents the estimated cash tax impact of certain items recorded
in each period that are added back in the calculation of Adjusted
Net Income/(Loss). The estimate is determined by applying the
statutory tax rate in tax paying jurisdictions to income or expense
items which impact cash taxes paid. Generally, amortization
attributable to purchase accounting, unrealized gains/losses due to
foreign currency translation and non-cash equity compensation do not
impact cash taxes.
|
|
|
|
|
|
|
|
|
|
|
|
Catalent, Inc. and Subsidiaries
|
|
|
Consolidated Balance Sheets
|
|
|
(Unaudited; Dollars in millions)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30, 2015
|
|
|
|
June 30, 2014
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
|
|
$
|
|
|
|
151.3
|
|
|
|
|
$
|
|
|
|
74.4
|
|
|
|
Trade receivables, net
|
|
|
|
|
372.4
|
|
|
|
|
403.7
|
|
|
|
Inventories
|
|
|
|
|
132.9
|
|
|
|
|
134.8
|
|
|
|
Prepaid expenses and other
|
|
|
|
|
80.9
|
|
|
|
|
74.6
|
|
|
|
Total current assets
|
|
|
|
|
737.5
|
|
|
|
|
687.5
|
|
|
|
Property, plant, and equipment, net
|
|
|
|
|
885.2
|
|
|
|
|
873.0
|
|
|
|
Other non-current assets, including intangible assets
|
|
|
|
|
1,522.7
|
|
|
|
|
1,529.7
|
|
|
|
Total assets
|
|
|
|
|
$
|
|
|
|
3,145.4
|
|
|
|
|
$
|
|
|
|
3,090.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST, AND
SHAREHOLDERS' EQUITY/(DEFICIT)
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
Current portion of long-term obligations and other short-term
borrowings
|
|
|
|
|
$
|
|
|
|
23.8
|
|
|
|
|
$
|
|
|
|
25.2
|
|
|
|
Accounts payable
|
|
|
|
|
128.2
|
|
|
|
|
148.1
|
|
|
|
Other accrued liabilities
|
|
|
|
|
247.0
|
|
|
|
|
279.7
|
|
|
|
Total current liabilities
|
|
|
|
|
399.0
|
|
|
|
|
453.0
|
|
|
|
Long-term obligations, less current portion
|
|
|
|
|
1,864.1
|
|
|
|
|
2,685.4
|
|
|
|
Other non-current liabilities
|
|
|
|
|
242.5
|
|
|
|
|
319.1
|
|
|
|
Redeemable noncontrolling interest
|
|
|
|
|
5.8
|
|
|
|
|
4.5
|
|
|
|
Commitment and contingencies (1)
|
|
|
|
|
|
|
|
|
|
|
|
Total shareholders' equity/(deficit)
|
|
|
|
|
634.0
|
|
|
|
|
(371.8
|
)
|
|
|
Total liabilities, redeemable noncontrolling interest and
shareholders' equity/(deficit)
|
|
|
|
|
$
|
|
|
|
3,145.4
|
|
|
|
|
$
|
|
|
|
3,090.2
|
|
|
|
|
(1)
|
|
Please refer to note 16 of the consolidated financial statements
within the Company’s Annual Report on Form 10-K for the fiscal year
ended June 30, 2015.
|
|
|
|
|
|
|
|
Catalent, Inc. and Subsidiaries
|
|
|
Consolidated Statements of Cash Flows
|
|
|
(Unaudited; Dollars in millions)
|
|
|
|
|
|
|
|
|
|
|
Twelve Months Ended June 30,
|
|
|
|
|
|
|
|
2015
|
|
|
|
2014
|
|
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by/(used in) operating activities from continuing
operations
|
|
|
|
|
$
|
|
|
|
171.7
|
|
|
|
|
$
|
|
|
|
180.2
|
|
|
|
Net cash provided by/(used in) operating activities from
discontinued operations
|
|
|
|
|
0.1
|
|
|
|
|
(1.9
|
)
|
|
|
Net cash provided by/(used in) operating activities
|
|
|
|
|
171.8
|
|
|
|
|
178.3
|
|
|
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
Acquisition of property and equipment and other productive assets
|
|
|
|
|
(141.0
|
)
|
|
|
|
(122.4
|
)
|
|
|
Proceeds from sale of property and equipment
|
|
|
|
|
—
|
|
|
|
|
0.9
|
|
|
|
Payment for acquisitions, net
|
|
|
|
|
(130.8
|
)
|
|
|
|
(53.7
|
)
|
|
|
Net cash provided by/(used in) investing activities from continuing
operations
|
|
|
|
|
(271.8
|
)
|
|
|
|
(175.2
|
)
|
|
|
Net cash provided by/(used in) investing activities from
discontinued operations
|
|
|
|
|
—
|
|
|
|
|
4.0
|
|
|
|
Net cash provided by/(used in) investing activities
|
|
|
|
|
(271.8
|
)
|
|
|
|
(171.2
|
)
|
|
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
Net change in short-term borrowings
|
|
|
|
|
—
|
|
|
|
|
(17.5
|
)
|
|
|
Proceeds from borrowing, net
|
|
|
|
|
150.4
|
|
|
|
|
1,723.7
|
|
|
|
Payments related to long-term obligations
|
|
|
|
|
(879.8
|
)
|
|
|
|
(1,741.3
|
)
|
|
|
Call premium payments and financing fees paid
|
|
|
|
|
(12.6
|
)
|
|
|
|
(7.2
|
)
|
|
|
Equity contribution/(redemption)
|
|
|
|
|
948.8
|
|
|
|
|
0.2
|
|
|
|
Share settlement
|
|
|
|
|
(10.3
|
)
|
|
|
|
—
|
|
|
|
Net cash (used in)/provided by financing activities from continuing
operations
|
|
|
|
|
196.5
|
|
|
|
|
(42.1
|
)
|
|
|
Net cash (used in)/provided by financing activities from
discontinued operations
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
Net cash (used in)/provided by financing activities
|
|
|
|
|
196.5
|
|
|
|
|
(42.1
|
)
|
|
|
Effect of foreign currency on cash
|
|
|
|
|
(19.6
|
)
|
|
|
|
3.0
|
|
|
|
NET INCREASE/(DECREASE) IN CASH AND EQUIVALENTS
|
|
|
|
|
76.9
|
|
|
|
|
(32.0
|
)
|
|
|
CASH AND EQUIVALENTS AT BEGINNING OF PERIOD
|
|
|
|
|
74.4
|
|
|
|
|
106.4
|
|
|
|
CASH AND EQUIVALENTS AT END OF PERIOD
|
|
|
|
|
$
|
|
|
|
151.3
|
|
|
|
|
$
|
|
|
|
74.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investor:
Catalent, Inc.
Thomas Castellano, 732-537-6325
investors@catalent.com